Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.

ABSTRACT:

Aim

The aim of this study was to systemically evaluate the therapeutic efficacy of cytokine-induced killer (CIK) cells for the treatment of non-small cell lung cancer.

Materials and methods

A computerized search of randomized controlled trials for CIK cell-based therapy was performed. The overall survival, clinical response rate, immunological assessment and side effects were evaluated.

Results

Overall, 17 randomized controlled trials of non-small cell lung cancer (NSCLC) with a total of 1172 patients were included in the present analysis. Our study showed that the CIK cell therapy significantly improved the objective response rate and overall survival compared to the non-CIK cell-treated group. After CIK combined therapy, we observed substantially increased percentag

SUBMITTER: Wang M 

PROVIDER: S-EPMC4239020 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature